GTC Biotherapeutics (fka GTCB)

[biopearl]

Can anyone verify the date of the expert FDA panel a the web site (or TV) for real time observation of the procedings? I think the future bodes well for 1. An Obama administration that will approach medical cost containment by innovation and support new technologies that do this. 2. A favorable view of Atryn as a very pure drug that does away with the standard risks associated with plasma derived drugs. 3. A public relations campaign that has been paid for in the past by GTCB dollars that could not be brought to bear because of prior dissapointments in the US market. It is waiting to burst free. 4. Pressure for "off label" use in sepsis especially if the phase II in Europe shows no worsening of an already terrible prognosis. And a question. Since we are dealing with a drug and an unmet need. If the experts recommend, what are the chances of an FDA ruling considerably before the Feb 7th date? Regards, bp